|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.680 USD | -4.19% |
|
-0.69% | +12.29% |
| Capitalization | 437M 374M 348M 324M 599M 37.53B 665M 4.17B 1.6B 17.57B 1.64B 1.61B 64.45B | P/E ratio 2025 * |
-52x | P/E ratio 2026 * | -5.77x |
|---|---|---|---|---|---|
| Enterprise value | 222M 190M 177M 165M 305M 19.09B 338M 2.12B 812M 8.94B 834M 817M 32.78B | EV / Sales 2025 * |
0.66x | EV / Sales 2026 * | 0.45x |
| Free-Float |
92.61% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: REGENXBIO Inc.
More recommendations
More press releases
More news
| 1 day | -4.19% | ||
| 1 week | -0.69% | ||
| Current month | +5.72% | ||
| 1 month | -14.90% | ||
| 3 months | +47.37% | ||
| 6 months | +15.58% | ||
| Current year | +12.29% |
| 1 week | 8.39 |  | 9.27 |
| 1 month | 7.82 | | 10.26 |
| Current year | 5.04 | | 11 |
| 1 year | 5.04 | | 15.36 |
| 3 years | 5.04 | | 35.73 |
| 5 years | 5.04 | | 50.26 |
| 10 years | 5.04 | | 85.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
Curran Simpson
CEO | Chief Executive Officer | 63 | 30/06/2024 |
Mitchell Chan
DFI | Director of Finance/CFO | 44 | 15/09/2024 |
Stephen Pakola
CTO | Chief Tech/Sci/R&D Officer | 56 | 16/04/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Allan Fox
CHM | Chairman | 77 | 30/06/2020 |
Kenneth Mills
CHM | Chairman | 50 | 30/06/2024 |
| Director/Board Member | 72 | 30/04/2015 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 0.25% | 23 M€ | -3.82% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -4.19% | -0.69% | -31.71% | -68.57% | 437M | ||
| -1.01% | +2.87% | +11.77% | +33.47% | 34.39B | ||
| +9.99% | +8.94% | +98.74% | -28.56% | 30.84B | ||
| -0.90% | +2.63% | +33.28% | -32.19% | 27.8B | ||
| +1.57% | +0.39% | +27.46% | +321.37% | 18.65B | ||
| -3.40% | +1.83% | +188.02% | +2,400.00% | 18.57B | ||
| +3.70% | +1.72% | +139.66% | -65.41% | 13.81B | ||
| -1.18% | +6.12% | -23.36% | -44.81% | 13.28B | ||
| +4.52% | -2.50% | +195.56% | +385.84% | 12.94B | ||
| -0.69% | -2.80% | +98.94% | +117.45% | 12.23B | ||
| Average | +0.84% | +2.89% | +73.84% | +301.86% | 18.3B | |
| Weighted average by Cap. | +1.63% | +4.26% | +75.02% | +299.69% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 336M 287M 268M 249M 460M 28.82B 511M 3.21B 1.23B 13.49B 1.26B 1.23B 49.49B | 284M 243M 226M 210M 389M 24.36B 432M 2.71B 1.04B 11.4B 1.06B 1.04B 41.83B |
| Net income | 5.12M 4.38M 4.08M 3.79M 7.01M 439M 7.79M 48.87M 18.69M 206M 19.21M 18.81M 755M | -110M -94.43M -87.96M -81.81M -151M -9.48B -168M -1.05B -403M -4.44B -414M -406M -16.27B |
| Net Debt | -215M -184M -171M -159M -294M -18.44B -327M -2.05B -784M -8.63B -806M -789M -31.67B | -309M -264M -246M -229M -423M -26.51B -470M -2.95B -1.13B -12.41B -1.16B -1.14B -45.54B |
More financial data
* Estimated data
Employees
353
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/07/25 | 8.680 $ | -4.19% | 403,298 |
| 10/07/25 | 9.060 $ | -1.20% | 476,348 |
| 09/07/25 | 9.170 $ | +4.92% | 552,687 |
| 08/07/25 | 8.740 $ | +3.68% | 620,771 |
| 07/07/25 | 8.430 $ | -3.55% | 679,975 |
Delayed Quote Nasdaq, July 11, 2025 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
8.680USD
Average target price
31.42USD
Spread / Average Target
+261.94%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- RGNX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition